Results 111 to 120 of about 1,543,966 (410)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies [PDF]

, 2022
Christopher T. Ritchlin, Philip J. Mease, Wolf‐­Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, A. Kollmeier, Xie L. Xu, M. Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar   +15 more
openalex   +1 more source

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Annals of the Rheumatic Diseases, 2016
Objective To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA).
P. Mease, D. M. van der Heijde, C. Ritchlin, M. Okada, R. Cuchacovich, C. Shuler, Chen-Yen Lin, D. Braun, Chin H Lee, D. Gladman   +9 more
semanticscholar   +1 more source

Assessment of skin in patients with systemic sclerosis using high‐frequency ultrasound and shear wave elastography: A comparative study with histology, molecular and clinical parameters

Arthritis Care &Research, Accepted Article.
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histological markers of skin fibrosis has not been reported. We evaluated the US‐based skin assessments for their face validity (differentiation between involved SSc and ...
Ruhani Desai, Filemon Tan, Minghua Wu, Jeffery L. Browning, Samuel Theodore, Meng Zhang, Brian Skaug, Harshdeep Singh Chawla, Manmohan Singh, Salavat Aglyamov, Kirill V. Larin, Maureen Mayes, Shervin Assassi   +12 more
wiley   +1 more source

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

The Placebo Effect in Pain Therapies.

Annual Review of Pharmacology and Toxicology, 2019
Pharmacological strategies for pain management have primarily focused on dampening ascending neurotransmission and on opioid receptor-mediated therapies.
L. Colloca
semanticscholar   +1 more source

Diffusion‐Weighted Imaging for the Evaluation of the Sacroiliac Joint in Pediatric Patients

Arthritis Care &Research, Accepted Article.
Background Maturational signal in the sacroiliac joint (SIJ) of skeletally immature youth is often misinterpreted as inflammation. Diagnostic tools that improve specificity are greatly needed. Apparent diffusion coefficient (ADC) values from diffusion‐weighted imaging (DWI), when used with standard imaging, may enhance diagnostic accuracy.
Michael L. Francavilla, Timothy G. Brandon, Dmitry Khrichenko, Rui Xiao, Nancy A. Chauvin, Asef Khwaja, Pamela F. Weiss   +6 more
wiley   +1 more source

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial [PDF]

, 2009
<br>Background: Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes.</br&
Eddy, Despres, Grundy, Bird, Seifarth, Nathan, Fontbonne, Charles, Holman, Kooy, Knowler, Alberti, Vergeer, Touboul, Liang, Spence, Levey, Meaney, Taylor, Selvin, Boussageon, Sjöström, Shyangdan, de Jager, Bots, Taylor, Boden, Huang, Baigent, Lorenz, Mazzone, Taylor, Lonn, Lexis   +33 more
core   +5 more sources

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

A novel formulation for radiotherapy-induced oral mucositis: Triamcinolone acetonide mucoadhesive film

Journal of Research in Medical Sciences, 2019
Background: The main purpose of this study was to evaluate the effectiveness of triamcinolone acetonide (TA) mucoadhesive films versus placebo as a preventive and therapeutic intervention of oral mucositis (OM) induced by radiotherapy for head-and-neck ...
Fahimeh Pakravan, Parichehr Ghalayani, Hamid Emami, Mehdi Nasr Isfahani, Pegah Noorshargh   +4 more
doaj   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources